Integrating Momelotinib: NCCN Guidelines and Drug Comparison

Aaron Gerds, MD, MS, explores the FDA approval of momelotinib and its swift integration into National Comprehensive Cancer Network (NCCN) guidelines. He reviews different JAK inhibitors based on adverse effects and treatment goals, addressing potential treatment-related anemia in myelofibrosis.

Related Keywords

Aaron Gerds , , Myelofibrosis , Myeloproliferative Neoplasms , Clinical Features , Prevalence , Quality Of Life , Cytokine Mediated Symptoms , Anemia , Chronic Illness , Disease Burden , Patient Characteristics , Jak Inhibitors , Nccn Guidelines , Anemia Intervention , Momelotinib , Category Recommendations , Evidence Blocks , Symptomatic High Risk ,